Skip to content
10-K/A

Annual Report

DAY ONE BIOPHARMACEUTICALS, INC.

0000950170-25-034878

← back to feed
Filed
Mar 6, 2025 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 20, 2025 101.35M sh
Shares Diluted FY 2024 · Dec 31, 2024 93.23M sh
Shares Diluted FY 2024 · Dec 31, 2023 79.77M sh
Shares Diluted FY 2024 · Dec 31, 2022 65.47M sh
Capex FY 2024 · Dec 31, 2024 $2.17M
Capex FY 2024 · Dec 31, 2023 $224K
Capex FY 2024 · Dec 31, 2022 $26K
Operating Cash Flow FY 2024 · Dec 31, 2024 −$78.11M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$146.85M
Operating Cash Flow FY 2024 · Dec 31, 2022 −$109.87M
Short Term Investments FY 2024 · Dec 31, 2024 $406.75M
Short Term Investments FY 2024 · Dec 31, 2023 $135.56M
Cash And Equivalents FY 2024 · Dec 31, 2024 $124.97M
Cash And Equivalents FY 2024 · Dec 31, 2023 $230.78M
Stockholders Equity FY 2024 · Dec 31, 2024 $502.75M
Stockholders Equity FY 2024 · Dec 31, 2023 $346.54M
Stockholders Equity FY 2024 · Dec 31, 2022 $332.04M
Stockholders Equity FY 2024 · Dec 31, 2021 $281.15M
Current Liabilities FY 2024 · Dec 31, 2024 $73.45M
Current Liabilities FY 2024 · Dec 31, 2023 $29.51M
Total Liabilities FY 2024 · Dec 31, 2024 $80.04M
Total Liabilities FY 2024 · Dec 31, 2023 $29.51M
Current Assets FY 2024 · Dec 31, 2024 $562.33M
Current Assets FY 2024 · Dec 31, 2023 $375.27M
Total Assets FY 2024 · Dec 31, 2024 $582.79M
Total Assets FY 2024 · Dec 31, 2023 $376.05M
Eps Diluted FY 2024 · Dec 31, 2024 −$1.02
Eps Diluted FY 2024 · Dec 31, 2023 −$2.37
Eps Diluted FY 2024 · Dec 31, 2022 −$2.17
Eps Basic FY 2024 · Dec 31, 2024 −$1.02
Eps Basic FY 2024 · Dec 31, 2023 −$2.37
Eps Basic FY 2024 · Dec 31, 2022 −$2.17
Sga Expense FY 2024 · Dec 31, 2024 $115.45M
Sga Expense FY 2024 · Dec 31, 2023 $75.54M
Sga Expense FY 2024 · Dec 31, 2022 $61.29M
Rd Expense FY 2024 · Dec 31, 2024 $227.7M
Rd Expense FY 2024 · Dec 31, 2023 $130.52M
Rd Expense FY 2024 · Dec 31, 2022 $85.62M
Operating Income FY 2024 · Dec 31, 2024 −$217.27M
Operating Income FY 2024 · Dec 31, 2023 −$206.06M
Operating Income FY 2024 · Dec 31, 2022 −$146.91M
Revenue FY 2024 · Dec 31, 2024 $131.16M
Revenue FY 2024 · Dec 31, 2023 $0
Revenue FY 2024 · Dec 31, 2022 $0